Zydus announces Phase IV EVIDENCES-XI trial to generate RWE of Saroglitazar Mg in NAFLD patients… EP News Bureau Jun 9, 2023 Phase IV EVIDENCES- XI trial will enroll approximately 1500 NAFLD patients with comorbidities
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData EP News Bureau Nov 23, 2020 The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029
